The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...
SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...
Since then, Alnylam has claimed approval for two more RNAis, Givlaari (givosiran) for acute hepatic porphyria (AHP) and Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1). RNAi uses small ...
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).
The FDA has granted a pair of designations, both orphan drug and rare pediatric disease, to ABO-101 (Arbor Biotechnologies) for the treatment of primary hyperoxaluria type 1 (PH1), according to a ...